Possible immunomodulating effect ketoprofen and ketoprofen lysine salt on the brain

• Autorzy: Nieradko-Iwanicka Barbara , Ruszel Kinga , Herbet Mariola , Pawłowski Kamil

Identyfikatory

DOI

10.2478/phr-2024-0018

Warianty tytułu

PL

Możliwe działanie immunomodulujące ketoprofenu i soli lizyny ketoprofenu na mózg

• Języki publikacji: EN PL

Abstrakty

EN

Ketoprofen lysine salt (KL) is a new non steroidal antiinflammatory drug (NSAID) competing with ketoprofen (K) on the market. The former is believed to have gastroprotective properies, the latter to kill acute pain. Many people drink ethanol and use NSAIDs on the days after.The aim of the study was to find out if K and KL have any immunomodulating effect on the brain after ethyl alcohol intoxication in a rat model. The experiment was carried out on 36 female Wistar rats. Animals were bred at the Experimental Medicine Centre at the Medical University of Lublin. The ethanol, NaCl, K and KL were administered by gavage. The animals were randomly divided into groups of 6.On day 7 all animals were sacrificed. Their brains and blood were collected for laboratory tests. There were no statistically significant differences in the concentration of IL-10 in the central nervous system between the study groups. We observed a positive correlation between brain IL-10 levels and body weight, also a correlation between brain IL-6 and brain weight. The level of IL-10 in the brain correlated with the concentration of IL-6 of all animals. Conclusions KL and K have some immunomodulating effect on the brain. There is a positive correlation between the level of IL-6 and IL-10 in rat brains.

PL

Sól lizynowa ketoprofenu (KL) jest nowym niesteroidowym lekiem przeciwzapalnym (NLPZ) konkurującym na rynku z ketoprofenem (K). Uważa się, że ten pierwszy ma właściwości gastroprotekcyjne, drugi uśmierza ostry ból. Wiele osób pije alkohol, a następnego dnia zażywa NLPZ. Celem badania było sprawdzenie, czy K i KL mają jakikolwiek wpływ immunomodulujący na mózg po zatruciu alkoholem etylowym na modelu szczurzym. Doświadczenie przeprowadzono na 36 samicach szczurów rasy Wistar. Zwierzęta hodowano w Centrum Medycyny Doświadczalnej Uniwersytetu Medycznego w Lublinie. Etanol, NaCl, K i KL podawano przez zgłębnik. Zwierzęta podzielono losowo na grupy po 6 sztuk. W 7 dniu wszystkie zwierzęta uśmiercono. Pobrano im mózgi i krew do badań laboratoryjnych. Nie stwierdzono istotnych statystycznie różnic w stężeniu IL-10 w ośrodkowym układzie nerwowym pomiędzy grupami badanymi. Zaobserwowaliśmy dodatnią korelację między poziomem IL-10 w mózgu a masą ciała, a także korelację między IL-6 w mózgu a masą mózgu. Poziom IL-10 w mózgu korelował ze stężeniem IL-6 u wszystkich zwierząt. Wnioski: KL i K mają pewien wpływ immunomodulujący na mózg. Istnieje dodatnia korelacja pomiędzy poziomem IL-6 i IL-10 w mózgach szczurów.

Słowa kluczowe

EN

immunomodulation; ketoprofen; ketoprofen lysine salt; interleukin-10; interleukin-6

PL

immunomodulacja; ketoprofen; sól lizynowa ketoprofenu; interleukina-10; interleukina-6

• Wydawca: Polskie Towarzystwo Medycyny i Techniki Hiperbarycznej
• Czasopismo: Polish Hyperbaric Research
• Rocznik: 2024
• Tom: nr 3(88)
• Strony: 87--98
• Opis fizyczny: Bibliogr. 42 poz., tab.

Twórcy

autor

Nieradko-Iwanicka Barbara

• Hygiene and Epidemiology Department, Medical University of Lublin, Poland

autor

Ruszel Kinga

• Doctoral School, Medical University of Lublin, Poland

autor

Herbet Mariola

• Katedra i Zakład Toksykologii, Uniwersytet Medyczny w Lublinie

autor

Pawłowski Kamil

• Katedra i Zakład Toksykologii, Uniwersytet Medyczny w Lublinie

Bibliografia

• 1. Avouac B., Teule M.1988. Ketoprofen: the European experience. J Clin Pharmacol, 28(s1):S2-7
• 2. Novelli R., Aramini A., Boccella S., Bagnasco M., Cattani F., Ferrari M.P., Goisis G., Minnella E.M., Allegretti M., Pace V.2022. Ketoprofen lysine salt has a better gastrointestinal and renal tolerability than ketoprofen acid: A comparative tolerability study in the Beagle dog. Biomed Pharmacother,153:113336.
• 3. Brandolini L., d'Angelo M., Antonosante A., Villa S., Cristiano L., Castelli V., Benedetti E., Catanesi M., Aramini A., Luini A., Parashuraman S., Mayo E., Giordano A., Cimini A., Allegretti M.2018. Differential protein modulation by ketoprofen and ibuprofen underlines different cellular response by gastric epithelium. J Cell Physiol,233(3):2304-2312.
• 4. Cimini A., Brandolini L., Gentile R., Cristiano L., Menghini P., Fidoamore A., Antonosante A., Benedetti E., Giordano A., Allegretti M. 2015.Gastroprotective effects of L-lysine salification of ketoprofen in ethanol-injured gastric mucosa. J Cell Physiol,230(4):813-20.
• 5. Aramini A., Bianchini G., Lillini S., Bordignon S., Tomassetti M., Novelli R., Mattioli S., Lvova L., Paolesse R., Chierotti M.R., Allegretti M.2021. Unexpected Salt/Cocrystal Polymorphism of the Ketoprofen-Lysine System: Discovery of a New Ketoprofen-l-Lysine Salt Polymorph with Different Physicochemical and Pharmacokinetic Properties. Pharmaceuticals (Basel),14(6):555.
• 6. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S.2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta,1813(5):878-88.
• 7. Kaplanski G., Marin V., Montero-Julian F., Mantovani A., Farnarier C.2002. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol,24(1):25-9.
• 8. Romano M., Sironi M., Toniatti C., Polentarutti N., Fruscella P., Ghezzi P., Faggioni R., Luini W., van Hinsbergh V., Sozzani S., Bussolino F., Poli V., Ciliberto G., Mantovani A. 1997.Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity,6(3):315-25.
• 9. Chen Q., Wang W.C., Bruce R., Li H., Schleider D.M., Mulbury M.J., Bain M.D., Wallace P.K., Baumann H., Evans S.S.2004. Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. Immunity,20(1):59-70.
• 10. Matthews V.B., Allen T.L., Risis S., Chan M.H., Henstridge D.C., Watson N., Zaffino L.A., Babb J.R., Boon J., Meikle P.J., Jowett J.B., Watt M.J., Jansson J.O., Bruce C.R., Febbraio M.A. 2010.Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia,53(11):2431-41.
• 11. Wunderlich F.T., Ströhle P., Könner A.C., Gruber S., Tovar S., Brönneke H.S., Juntti-Berggren L., Li L.S., van Rooijen N., Libert C., Berggren P.O., Brüning J.C.2010. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab,12(3):237-49.
• 12. Nishimoto N., Kanakura Y., Aozasa K., Johkoh T., Nakamura M., Nakano S., Nakano N., Ikeda Y., Sasaki T., Nishioka K., Hara M., Taguchi H., Kimura Y., Kato Y., Asaoku H., Kumagai S., Kodama F., Nakahara H., Hagihara K., Yoshizaki K., Kishimoto T.2005. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 106(8):2627-32.
• 13. Peters M., Schirmacher P., Goldschmitt J., Odenthal M., Peschel C., Fattori E., Ciliberto G., Dienes H.P., Meyer zum Büschenfelde K.H., Rose-John S. 1997.Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med,185(4):755-66.
• 14. Febbraio M.A., Rose-John S., Pedersen B.K.2010. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther,87(4):396-8.
• 15. Obreja O., Schmelz M., Poole S., Kress M.2002. Interleukin-6 in combination with its soluble IL-6 receptor sensitises rat skin nociceptors to heat, in vivo. Pain,96(1-2):57-62.
• 16. Murphy P.G., Ramer M.S., Borthwick L., Gauldie J., Richardson P.M., Bisby M.A. Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice. Eur J Neurosci,11(7):2243-53.
• 17. Sheppard M., Laskou F., Stapleton P.P., Hadavi S., Dasgupta B.2017. Tocilizumab (Actemra). Hum Vaccin Immunother,13(9):1972-1988.
• 18. Mollazadeh H., Cicero A.F.G., Blesso C.N., Pirro M., Majeed M., Sahebkar A.2019. Immune modulation by curcumin: The role of interleukin-10. Crit Rev Food Sci Nutr, 59(1):89-101.
• 19. Saraiva M., Vieira P., O'Garra A.2020. Biology and therapeutic potential of interleukin-10. J Exp Med,217(1):e20190418.
• 20. Kelley K.W., Dantzer R.2011. Alcoholism and inflammation: neuroimmunology of behavioral and mood disorders. Brain Behav Immun,25 Suppl 1(0 1):S13-20.
• 21. Aalykke C., Lauritsen K.2001. Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol,15(5):705-22.
• 22. Smaga A., Bogusławski S., Wróbel K., Wojtyniak B.2022. Rozpowszechnienie behawioralnych czynników ryzyka zdrowotnego i jego zmiany w okresie pandemii COVID-19.In: Wojtyniak B., Goryński P. Eds. Sytuacja zdrowotna ludności Polski i jej uwarunkowania 2022.Narodowy Instytut Zdrowia Publicznego PZH-– Państwowy Instytut Badawczy, Warszawa 2022 (In Polish).
• 23. Barbería-Latasa M., Gea A., Martínez-González M.A.2022. Alcohol, Drinking Pattern, and Chronic Disease. Nutrients,14(9):1954.
• 24. Aziz F., Chakraborty A., Liu K., Zhang T., Li X., Du R., Monts J., Xu G., Li Y., Bai R., Dong Z.2022. Gastric tumorigenesis induced by combining Helicobacter pylori infection and chronic alcohol through IL-10 inhibition. Carcinogenesis,43(2):126-139.
• 25. Aramini A., Bianchini G., Lillini S., Tomassetti M., Pacchiarotti N., Canestrari D., Cocchiaro P., Novelli R., Dragani M.C., Palmerio F., Mattioli S., Bordignon S., d'Angelo M., Castelli V., d'Egidio F., Maione S., Luongo L., Boccella S., Cimini A., Brandolini L., Chierotti M.R., Allegretti M.2023. Ketoprofen, lysine and gabapentin co-crystal magnifies synergistic efficacy and tolerability of the constituent drugs: Pre-clinical evidences towards an innovative therapeutic approach for neuroinflammatory pain. Biomed Pharmacother,163:114845.
• 26. Skurk T., Alberti-Huber C., Herder C., Hauner H.2007. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab,92(3):1023-33.
• 27. Hotamisligil G.S. 2006.Inflammation and metabolic disorders. Nature,444(7121):860-7.
• 28. Anesten F., Dalmau Gasull A., Richard J.E., Farkas I., Mishra D., Taing L., Zhang F., Poutanen M., Palsdottir V., Liposits Z., Skibicka K.P., Jansson J.O.2019. Interleukin-6 in the central amygdala is bioactive and co-localised with glucagon-like peptide-1 receptor. J Neuroendocrinol,31(6):e12722.
• 29. Bornath D.P.D., McKie G.L., McCarthy S.F., Vanderheyden L.W., Howe G.J., Medeiros P.J., Hazell T.J.2023. Interleukin-6 is not involved in appetite regulation following moderate-intensity exercise in males with normal weight and obesity. Obesity (Silver Spring),31(9):2315-2324.
• 30. Roleder N., Aringer M., Boentert M.2012. Role of interleukin-6 in stress, sleep, and fatigue. Ann N Y Acad Sci,1261:88-96.
• 31. Martinez F., Abril E.R., Earnest D.L., Watson R.R. 1992.Ethanol and cytokine secretion. Alcohol. 9(6):455-8.
• 32. Martins T.L., Kahvegian M.A., Noel-Morgan J., Leon-Román M.A., Otsuki D.A., Fantoni D.T.2010. Comparison of the effects of tramadol, codeine, and ketoprofen alone or in combination on postoperative pain and on concentrations of blood glucose, serum cortisol, and serum interleukin-6 in dogs undergoing maxillectomy or mandibulectomy. Am J Vet Res,71(9):1019-26.
• 33. Caton S.J., Nolan L.J., Hetherington M.M.2015. Alcohol, Appetite and Loss of Restraint. Curr Obes Rep,4(1):99-105.
• 34. Kuczyńska J., Nieradko-Iwanicka B.2021. The effect of ketoprofen lysine salt on mucosa of rat stomach after ethyl alcohol intoxication. Biomed Pharmacother,141:111938.
• 35. Arab H.H., Saad M.A., El-Sahar A.E., Al-Shorbagy M.Y.2020. Mechanistic perspective of morin protection against ketoprofen-induced gastric mucosal injury: Targeting HMGB1/RAGE/NF-κB, DJ-1/Nrf2/HO-1 and PI3K/mTOR pathways. Arch Biochem Biophys,693:108552.
• 36. Schunck R.V., Torres I.L., Laste G., de Souza A., Macedo I.C., Valle M.T., Salomón J.L., Moreira S., Kuo J., Arbo M.D., Dallegrave E., Leal M.B.2015. Protracted alcohol abstinence induces analgesia in rats: Possible relationships with BDNF and interleukin-10. Pharmacol Biochem Behav,135:64-9.
• 37. Murakami S., Imamura M., Uchida T., Suehiro Y., Namba M., Fujii Y., Uchikawa S., Teraoka Y., Fujino H., Ono A., Nakahara T., Murakami E., Okamoto W., Yamauchi M., Kawaoka T., Miki D., Hayes N.C., Tsuge M., Aikata H., Ohira M., Ohdan H., Oka S.2023. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure. Hepatol Int,17(5):1225-1232.
• 38. Tablov B., Stavreva S., Tablov V., Popov I., Konova E.2007. [Immunological aspects of postoperative analgesia after abdominal hysterectomy]. Akush Ginekol (Sofiia)46(1):18-24.
• 39. Kuczyńska J., Pawlak A., Nieradko-Iwanicka B.2022. The comparison of dexketoprofen and other painkilling medications (review from 2018 to 2021). Biomed Pharmacother,. 149:112819.
• 40. Piirainen A., Kokki M., Hautajärvi H., Lehtonen M., Miettinen H., Pulkki K., Ranta V.P., Kokki H.2016. The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. Clin Drug Investig,36(7):545-55.
• 41. Al-Hakeim H.K., Twayej A.J., Al-Dujaili A.H., Maes M.2020. Plasma indoleamine-2,3-dioxygenase (ido) is increased in drug-naïve major depressed patients and treatment with sertraline and ketoprofen normalizes ido in association with pro-inflammatory and immune-regulatory cytokines. CNS Neurol. Disord. - Drug Targets,19(1):44–54.
• 42. Kuczyńska J., Nieradko-Iwanicka B. 2023.Comparison of the effects of ketoprofen and ketoprofen lysine salt on the Wistar rats' nervous system, kidneys and liver after ethyl alcohol intoxication. Biomed Pharmacother,161:114456.